Eton Pharmaceuticals (NASDAQ: ETON) experienced a dramatic surge in its stock price on Friday, climbing more than 38% to a record high. The rare-disease drugmaker's shares were trading at $56.40 by mid-morning, up $15.60 from the previous close, after the company reported second-quarter results that significantly exceeded Wall Street expectations and raised its full-year guidance.
The company posted revenue of $37.6 million for the quarter, a 99% increase year-over-year and a 38.7% beat over the FactSet consensus estimate of $27.1 million. Adjusted earnings came in at $0.43 per share, well above the anticipated $0.19. The strong performance was driven by robust sales across its portfolio of ten marketed rare-disease products, including Increlex, Alkindi Sprinkle, Desmoda, and Hemangeol.
Management also lifted its 2026 revenue guidance to at least $145 million, up from a previous floor of $120 million. The company raised its adjusted EBITDA margin floor to 35% from 30%. The updated guidance includes a $3 million licensing payment from ASN-001 and assumes related research spending, as well as a potential $4 million milestone payment for Alkindi Sprinkle, making the quality of the revenue mix a key focus for investors.
The market's response was notable not just for the magnitude of the move but for the valuation signal it sent. The rally added approximately $427 million to Eton's equity value, which is roughly 17 times the $25 million increase in the annual revenue floor. This suggests investors are pricing in not only the guidance raise but also greater future operating leverage and product adoption.
Analysts were quick to adjust their outlooks. H.C. Wainwright and Craig-Hallum both reiterated buy ratings on Friday, with new price targets of $70 and $76, respectively. The average analyst target across four covering firms rose to $61.50, though the range remains wide—from B. Riley's $40 to Craig-Hallum's $76—highlighting the uncertainty surrounding the company's long-term trajectory.
The stock's performance stood out in a subdued market session, with the S&P 500 and Nasdaq hovering near records following weak retail sales data. The broader health-care sector showed modest gains, but Eton's surge was the standout event.
Despite the positive momentum, risks remain. Eton is a small pharmaceutical company with a concentrated product portfolio, and factors such as prescription uptake, reimbursement, manufacturing, and regulatory timelines could shift. One-time licensing or milestone revenue may also distort future comparisons. The next test will be the durability of sales growth and margin expansion, as the company must deliver recurring revenue to justify its new valuation.